Viral kinetic modeling: state of the art

Ho DD et al (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373(6510):123–126 Perelson AS (2002) Modelling viral and immune system dynamics. Nat Rev Immunol 2(1):28–36 Perelson AS et al (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188–191 Perelson AS et al (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271(5255):1582–1586 Wei X et al (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373(6510):117–122 Neumann AU et al (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282(5386):103–107 Ciupe SM et al (2007) The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc Natl Acad Sci USA 104(12):5050–5055 Ciupe SM et al (2007) Modeling the mechanisms of acute hepatitis B virus infection. J Theor Biol 247(1):23–35 Dahari H et al (2009) Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology 49(1):32–38 Lewin SR et al (2001) Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 34(5):1012–1020 Murray JM et al (2005) Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci USA 102(49):17780–17785 Nowak MA et al (1996) Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 93(9):4398–4402 Ribeiro RM et al (2010) Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. J Infect Dis 202(9):1309–1318 Ribeiro RM, Lo A, Perelson AS (2002) Dynamics of hepatitis B virus infection. Microb Infect 4(8):829–835 Emery VC, Griffiths PD (2000) Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 97(14):8039–8044 Emery VC et al (2012) Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy. J Clin Virol 54(1):56–60 Regoes RR et al (2006) Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis. Proc R Soc B 273(1596):1961–1967 Schiffer JT, Corey L (2013) Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med 19(3):280–288 Schiffer JT et al (2013) Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. Elife 2:e00288 Schiffer JT et al (2011) The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral–host interactions. J Infect Dis 204(4):554–561 Baccam P et al (2006) Kinetics of influenza A virus infection in humans. J Virol 80(15):7590–7599 Beauchemin C, Samuel J, Tuszynski J (2005) A simple cellular automaton model for influenza A viral infections. J Theor Biol 232(2):223–234 Bocharov GA, Romanyukha AA (1994) Mathematical model of antiviral immune response. III. Influenza A virus infection. J Theor Biol 167(4):323–360 Canini L, Carrat F (2011) Population modeling of influenza A/H1N1 virus kinetics and symptom dynamics. J Virol 85(6):2764–2770 Hancioglu B, Swigon D, Clermont G (2007) A dynamical model of human immune response to influenza A virus infection. J Theor Biol 246(1):70–86 Handel A, Longini IM Jr, Antia R (2010) Towards a quantitative understanding of the within-host dynamics of influenza A infections. J R Soc Interface 7(42):35–47 Miao H et al (2010) Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol 84(13):6687–6698 Pawelek KA et al (2012) Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comput Biol 8(6):e1002588 Saenz RA et al (2010) Dynamics of influenza virus infection and pathology. J Virol 84(8):3974–3983 Smith AM et al (2011) Effect of 1918 PB1-F2 expression on influenza A virus infection kinetics. PLoS Comput Biol 7(2):e1001081 Smith AM, Perelson AS (2011) Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip Rev Syst Biol Med 3(4):429–445 Perelson AS, Rong L, Hayden FG (2012) Combination antiviral therapy for influenza: predictions from modeling of human infections. J Infect Dis 205(11):1642–1645 Murillo LN, Murillo MS, Perelson AS (2013) Towards multiscale modeling of influenza infection. J Theor Biol 332:267–290 Smith AM et al (2013) Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog 9(3):e1003238 Asquith B, Bangham CR (2007) Quantifying HTLV-I dynamics. Immunol Cell Biol 85(4):280–286 Heffernan J, Keeling MJ (2008) An in-host model of acute infection: measles as a case study. Theor Popul Biol 73(1):134–147 Zhang J et al (2013) Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection. J Virol 87(7):4052–4059 Snoeck E et al (2010) A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 87(6):706–713 Guedj J et al (2014) Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in HCV genotype 2/3 patients. Hepatology 59(5):1706–1714 Gao M et al (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465(7294):96–100 Beauchemin CA et al (2008) Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol 254(2):439–451 Bochud P-Y et al (2011) IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 55(5):980–988 Dahari H et al (2011) Hepatitis C viral kinetics in the era of direct acting antiviral agents and interleukin-28B. Curr Hepat Rep 10(3):214–227 Guedj H et al (2012) The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with PEG-IFN-alfa-2a and ribavirin. J Viral Hepat 19(7):488–496 Guedj J et al (2012) Understanding silibinin’s modes of action against HCV using viral kinetic modeling. J Hepatol 56(5):1019–1024 Lagging M et al (2011) Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 6(2):e17232 Layden-Almer JE et al (2003) Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37(6):1343–1350 Neumann AU et al (2000) Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 182(1):28–35 Herrmann E et al (2003) Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37(6):1351–1358 Dahari H, Ribeiro RM, Perelson AS (2007) Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 46(1):16–21 Dahari H et al (2007) Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 247(2):371–381 Rong L et al (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2(30):30ra32 Dahari H et al (2010) Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol 53(3):460–467 Guedj J et al (2010) A perspective on modelling hepatitis C virus infection. J Viral Hepat 17(12):825–833 Shudo E, Ribeiro RM, Perelson AS (2009) Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol 5(3):321–332 Talal AH et al (2006) Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 43(5):943–953 Adiwijaya BS et al (2012) A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput Biol 8(1):e1002339 Powers KA et al (2003) Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 23:13–18 Holford NH, Sheiner LB (1981) Understanding the dose–effect relationship. Clin Pharmacokinet 6(6):429–453 Guedj J et al (2012) Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 55(4):1030–1037 Shudo E et al (2008) A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther 13(7):919–926 Shudo E, Ribeiro R, Perelson A (2008) Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon α-2b. J Viral Hepat 15(5):379–382 Conway JM, Perelson AS (2014). Hepatitis C virus infection model with time-varying drug effectivenss: solution and analysis (submitted) Guedj J et al (2014) Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther 19(2):211–220 Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47(2):331–385 Ribeiro RM et al (2012) Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 8(8):e1002881 Drake JW et al (1998) Rates of spontaneous mutation. Genetics 148(4):1667–1686 Kieffer T et al (2007) Evaluation of viral variants during a Phase 2 study (PROVE2) of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype 1-infected patients. Hepatology 46(Suppl 1):862 Rong L, Ribeiro RM, Perelson AS (2012) Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull Math Biol 74(8):1789–1817 Adiwijaya BS et al (2010) A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol 6(4):e1000745 Guedj J et al (2013) Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA 110(10):3991–3996 Rong L, Perelson AS (2013) Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents. Math Biosci 245(1):22–30 Rong L et al (2013) Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol 9(3):e1002959 Kandathil AJ et al (2013) Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology 145(6):1404.e10–1413.e10 Graw F et al (2014) Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes (submitted) Graw F, Perelson AS (2013) Spatial aspects of HIV infection. In: Mathematical methods and models in biomedicine. Springer, Berlin, pp 3–31 Bauer AL, Beauchemin CA, Perelson AS (2009) Agent-based modeling of host–pathogen systems: the successes and challenges. Inf Sci 179(10):1379–1389 Chao DL et al (2010) FluTE, a publicly available stochastic influenza epidemic simulation model. PLoS Comput Biol 6(1):e1000656 Ferguson NM et al (2005) Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437(7056):209–214 Mills CE, Robins JM, Lipsitch M (2004) Transmissibility of 1918 pandemic influenza. Nature 432(7019):904–906 Jansen CA et al (2013) Differential lung NK cell responses in avian influenza virus infected chickens correlate with pathogenicity. Sci Rep 3:2478 Pommerenke C et al (2012) Global transcriptome analysis in influenza-infected mouse lungs reveals the kinetics of innate and adaptive host immune responses. PLoS ONE 7(7):e41169 Belz GT et al (2002) Compromised influenza virus-specific CD8+-T-cell memory in CD4+-T-cell-deficient mice. J Virol 76(23):12388–12393 Tridane A, Kuang Y (2010) Modeling the interaction of cytotoxic T lymphocytes and influenza virus infected epithelial cells. Math Biosci Eng 7(1):171–185 Ginaldi L et al (2001) Immunosenescence and infectious diseases. Microbes Infect 3(10):851–857 Hernandez-Vargas EA et al (2014) The effects of aging on influenza virus infection dynamics. J Virol 88(8):4123–4131 Hayden FG et al (1998) Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Investig 101(3):643 Anderson RM, May RM (1982) Directly transmitted infectious diseases: control by vaccination. Science 215(4536):1053–1060 Handel A, Longini IM Jr, Antia R (2007) Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput Biol 3(12):e240 Canini L et al (2014) Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study. PLoS Comput Biol 10(4):e1003568 Heldt FS et al (2013) Multiscale modeling of influenza A virus infection supports the development of direct-acting antivirals. PLoS Comput Biol 9(11):e1003372 Guedj J, Perelson AS (2011) Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 53(6):1801–1808 Adiwijaya BS et al (2011) Modeling clinical and virology data from phase 2 and 3 studies support 12-week telaprevir duration in combination with 24- or 48-week peginterferon/ribavirin. Gastroenterology 140(5):943 Kohli A et al (2014) Hepatitis C antiviral therapy for 6 or 12 weeks: final results of the SYNERGY trial. In: Conference on retroviruses and opportunistic infections, 2014 Wieland S et al (2014) Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 59(6):2121–2130 Sidharthan S et al (2014) Predicting response to all-oral directly acting antiviral therapy for hepatitis C using results of Roche and Abbott HCV viral load assays. Hepatol Int 8(S1):S227–S228 Cowling BJ et al (2010) Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 362(23):2175–2184 Atkinson A, Donev A (1992) Optimum experimental designs. Clarendon, Oxford Canini L, Carrat F (2011) Viral kinetics studies on influenza: when and how many times are nasal samples to be collected? Influenza Other Respir Viruses 5(S1):144–147 Gustin KM et al (2011) Influenza virus aerosol exposure and analytical system for ferrets. Proc Natl Acad Sci USA 108(20):8432–8437 Eccles R (2005) Understanding the symptoms of the common cold and influenza. Lancet Infect Dis 5(11):718–725